Sean Whooley

Sean Whooley is a journalist with a focus on medical technology reporting. He holds a bachelor's degree in multiplatform journalism from the University of Maryland, College Park and serves as an associate editor for MassDevice, Medical Design & Outsourcing, and Drug Delivery Business News. In his work, he covers topics such as FDA approvals for medical devices, studies on Medtronic's TAVR system, and acquisitions in the industry like Bio-Rad's purchase of Curiosity Diagnostics. Through these articles, Whooley demonstrates an understanding of the primary topics within medical technology and maintains a neutral tone while providing balanced information.

94%

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

92%

Examples:

  • The author seems to favor the companies they report on, but provides balanced information and cites multiple sources.

Conflicts of Interest

92%

Examples:

  • The author is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. This may create a conflict of interest as the articles are likely to be favorable towards the companies they report on.

Contradictions

100%

Examples:

  • No major contradictions found in the articles.

Deceptions

100%

Examples:

  • No deceptive practices found in the articles.

Recent Articles

Medtronic's Game-Changing Inceptiv: The World's First Closed-Loop Spinal Cord Stimulator for Personalized Chronic Pain Relief

Medtronic's Game-Changing Inceptiv: The World's First Closed-Loop Spinal Cord Stimulator for Personalized Chronic Pain Relief

Broke On: Friday, 26 April 2024 Medtronic's new Inceptiv closed-loop spinal cord stimulator, the world's smallest and thinnest fully implantable system, offers personalized chronic pain relief through real-time adjustments based on biological signals. The device features a rechargeable lithium battery and MRI access with no restrictions.

Recent Studies Highlight Effectiveness and Potential Risks of TAVR in Treating Aortic Stenosis

Broke On: Sunday, 01 October 2023 Recent studies have shown that Transcatheter Aortic Valve Replacement (TAVR) is effective in treating aortic stenosis in low-risk patients. The PARTNER 3 and Evolut trials found that TAVR outperformed surgical aortic valve replacement (SAVR) in terms of mortality, stroke, and rehospitalization rates at one year. A separate study found that adding left atrial appendage occlusion (LAAO) to TAVR did not increase the risk of complications.